Why an Unnamed AI Drug‑Discovery Startup Commands a $20 B Valuation Before It Exists
The article analyzes why a pre‑launch AI‑driven pharma company can attract a $20 billion valuation, detailing the efficiency promises of AI, the evolving technology stack, the scarcity of talent, and the real bottlenecks that still limit drug discovery.
